AGN Allergan Plc
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.
Company profile
Ticker
AGN
Exchange
CEO
Brenton L. Saunders
Employees
Incorporated in
Location
Fiscal year end
Industry (SEC)
Former names
Actavis Ltd, Actavis plc
SEC CIK
Corporate docs
AGN stock data
()
Calendar
8 Aug 19
15 Sep 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Dec 18 | Sep 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|
| Revenue | 4.08B | 3.91B | 4.12B | 3.67B | |
| Net income | -4.3B | -37.9M | -472.5M | -286.1M | |
| Diluted EPS | -12.83 | -0.11 | -1.39 | -0.99 | |
| Net profit margin | -105% | -0.97% | -11.46% | -7.79% | |
| Operating income | -5.38B | 257.5M | -467M | -654M | |
| Net change in cash | -307.5M | -486.8M | 679.9M | -822.4M | |
| Cash on hand | 880.4M | 1.19B | 1.67B | 994.8M | |
| Cost of revenue | 590M | 596.8M | 481.8M | 522.8M |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 15.79B | 15.94B | 14.57B | 12.69B | |
| Net income | -5.1B | -4.13B | 14.97B | 3.92B | |
| Diluted EPS | -15.26 | -13.19 | 38.18 | 10.01 | |
| Net profit margin | -32.28% | -25.88% | 103% | 30.86% | |
| Operating income | -6.25B | -5.92B | -1.83B | -3.13B | |
| Net change in cash | -936.8M | 93.2M | 628M | 846M | |
| Cash on hand | 880.4M | 1.82B | 1.72B | 1.1B | |
| Cost of revenue | 2.19B | 2.17B | 1.86B | 2.75B |
Financial data from Allergan earnings reports
Financial report summary
?Competition
Akorn • TherapeuticsMD • Insite Vision • Medicis Pharmaceutical • Hologic • Veru • VIVUS • Cynosure • Uroplasty • Repros Therapeutics
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
AbbVie, accuracy, administering, advisor, Africa, Ajanta, Appendix, attention, attract, attractive, belief, beneficial, BIOCELL, biopharmaceutical, Brazil, broad, calcitonin, Ceniciviroc, CGRP, China, clause, compensatory, competent, compliance, conflict, consultation, consummate, consummated, consummation, Council, deal, decree, deprioritized, devoted, discourage, disruption, divert, duly, EC, efficient, enterprise, evidentiary, exceeded, Exhibit, extent, extraordinary, failure, Food, frame, Furnished, geographic, grow, hand, herewith, holder, iii, impose, incidence, Index, Instance, Interaction, intrinsic, Japan, Kingdom, knowledge, Korea, Label, lesser, Linkbase, long, Matthew, member, membership, Mexico, motivate, pendency, peptide, percentage, point, precaution, preceding, printing, profile, profit, proxy, ratio, referral, registrant, Registrar, registration, relevant, replenishment, reputation, retention, safety, sanction, sentence, smaller, solicit, South, Takeover, Taxonomy, thereunto, thirty, timeframe, tissue, tribunal, Turkey, unable, unanticipated, uncommon, undersigned, unused, valuable, Venice, verdict, view, vote, voting, waiting, waived, Walsh, write, XBRL
Removed:
erosion, headroom, lifted, power, rare, responded, ruling
Financial reports
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
15 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
10-Q
2018 Q2
Quarterly report
3 Aug 18
10-Q/A
2018 Q1
Quarterly report (amended)
25 May 18
10-Q
2018 Q1
Quarterly report
3 May 18
10-K
2017 FY
Annual report
16 Feb 18
10-Q
2017 Q3
Quarterly report
2 Nov 17
10-Q
2017 Q2
Quarterly report
9 Aug 17
Current reports
8-K
Other Events
11 Sep 19
8-K
Results of Operations and Financial Condition
6 Aug 19
8-K
Allergan Reports Second Quarter 2019 Financial Results
6 Aug 19
8-K
This Announcement Is Being Made Pursuant to Rule 2.5 of the Irish Takeover Rules
25 Jun 19
8-K
Allergan Reports First Quarter 2019 Financial Results
7 May 19
8-K
Submission of Matters to a Vote of Security Holders
1 May 19
8-K
Other Events
22 Mar 19
8-K
Other Events
28 Feb 19
8-K
Departure of Directors or Certain Officers
19 Feb 19
8-K
Other Events
8 Feb 19
Registration and prospectus
424B2
Prospectus for primary offering
9 Nov 18
424B5
Prospectus supplement for primary offering
8 Nov 18
25-NSE
Exchange delisting
1 Mar 18
S-3ASR
Automatic shelf registration
16 Feb 18
SC TO-T/A
Third party tender offer statement (amended)
30 Jan 18
SC TO-T/A
Third party tender offer statement (amended)
5 Jan 18
SC TO-T/A
Third party tender offer statement (amended)
4 Jan 18
SC TO-T
Third party tender offer statement
29 Dec 17
S-8
Registration of securities for employees
9 May 17
SC TO-T/A
Third party tender offer statement (amended)
1 Nov 16
Proxies
DEFA14A
Additional proxy soliciting materials
11 Sep 19
PREM14A
Preliminary proxy related to merger
12 Aug 19
DEFA14A
Additional proxy soliciting materials
12 Jul 19
DEFA14A
Additional proxy soliciting materials
8 Jul 19
DEFA14A
Additional proxy soliciting materials
2 Jul 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19
DEFA14A
Additional proxy soliciting materials
27 Jun 19
Other
SD
Conflict minerals disclosure
23 May 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
UPLOAD
Letter from SEC
23 Feb 17
CORRESP
Correspondence with SEC
14 Feb 17
UPLOAD
Letter from SEC
7 Feb 17
UPLOAD
Letter from SEC
11 Jan 17
UPLOAD
Letter from SEC
11 Jan 17
CORRESP
Correspondence with SEC
10 Jan 17
UPLOAD
Letter from SEC
29 Dec 16